Xcision Medical Systems

Xcision Medical Systems is a private, commercial-stage medical device company pioneering stereotactic radiotherapy for breast cancer with its GammaPod system. The technology, cleared by the FDA, uses a rotating multi-source Cobalt-60 system and a proprietary breast immobilization cup to deliver precise, high-dose radiation in dramatically fewer sessions than standard care. The company targets the significant global breast cancer market by offering a non-surgical, cost-effective treatment that shortens therapy from weeks to days. Xcision is actively engaging with the clinical community and advocating for supportive reimbursement policies to drive adoption.

GammaPod: A dedicated stereotactic radiotherapy system for breast cancer using a rotating multi-source Cobalt-60 irradiator, a proprietary vacuum-assisted breast immobilization cup, and prone patient positioning to deliver precise, high-dose radiation in few sessions.

GammaPod's primary competitors are not other dedicated breast SBRT devices, but rather advanced linear accelerators (LINACs) from companies like Varian (a Siemens Healthineers company) and Elekta. These platforms, when equipped with motion management and advanced planning software, can be used to deliver hypofractionated breast radiotherapy. GammaPod's differentiation lies in its dedicated design, unique immobilization, and optimized physics for breast SBRT, but it must compete for capital budget against these versatile, multi-purpose machines.